Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Deal Size: $330.0 million Upfront Cash: $5.0 million
Deal Type: Collaboration November 02, 2020
The collaboration covers the discovery of novel oral gamma-aminobutyric acid receptor subtype B (GABAB) positive allosteric modulator (PAM) compounds as potential therapies for multiple disease areas.